C4 Therapeutics, Inc.
CCCC
$2.61
-$0.21-7.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.41% | -46.87% | 7.19% | 0.52% | 8.77% |
| Total Depreciation and Amortization | 4.07% | 37.28% | 1.79% | 11.63% | -1.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.82% | -5.06% | -0.61% | 26.42% | -2.54% |
| Change in Net Operating Assets | -78.11% | 23.50% | -511.62% | 118.13% | 33.31% |
| Cash from Operations | -29.31% | -142.40% | -83.71% | 25.31% | 21.41% |
| Capital Expenditure | -3,261.54% | 6.09% | -- | 102.55% | 102.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,918.12% | 439.79% | 154.55% | -57.43% | -99.74% |
| Cash from Investing | 2,422.22% | 432.49% | 154.55% | -57.21% | -99.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -25.85% | -- | -- | -99.81% | -- |
| Repurchase of Common Stock | 71.76% | -- | -42.20% | -- | -431.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -44.78% | -- | 29.76% | 200.00% | 12.93% |
| Cash from Financing | -26.01% | -100.00% | -100.13% | -99.81% | 197.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.69% | 262.37% | 88.61% | -106.33% | -182.79% |